NCT05433220

Brief Summary

A randomized, single-blind intervention trial to test the comparative effectiveness of an electronic health record best practice advisory system that informs clinicians of guideline-indicated and FDA-approved heart failure medications currently not prescribed to their patients with heart failure versus usual care (no alert and how things are done currently). The purpose of the alert is to stimulate appropriate medication prescription for patients with heart failure and a reduced ejection fraction. This will be done across outpatient Inova clinics and at the five Inova hospitals.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for not_applicable heart-failure

Timeline
2mo left

Started Aug 2022

Typical duration for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Aug 2022Aug 2026

First Submitted

Initial submission to the registry

June 21, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 27, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

August 25, 2022

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

August 24, 2025

Status Verified

August 1, 2025

Enrollment Period

3.8 years

First QC Date

June 21, 2022

Last Update Submit

August 19, 2025

Conditions

Keywords

Heart FailureGDMTNYHAHFrEFImplementation

Outcome Measures

Primary Outcomes (1)

  • Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction

    The primary outcome for the trial will be the proportion of patients with HFrEF who have an increase in the number of prescribed evidence-based therapies for HFrEF (beta-blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) 30 days after randomization.

    30 days after randomization

Secondary Outcomes (4)

  • All-cause hospitalization and all-cause mortality at 30 days

    30 days

  • All-cause hospitalization and all-cause mortality at 90 days

    90 days

  • All-cause hospitalization and all-cause mortality at 180 days

    180 days

  • All-cause hospitalization and all-cause mortality at 1 year

    1 year

Study Arms (2)

Alert when provider is entering orders

EXPERIMENTAL
Other: Best Practice Advisory using Electronic Health Record

No alert, usual care

NO INTERVENTION

Interventions

Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.

Alert when provider is entering orders

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age\>18 Years
  • Seen by a Cardiologist in an Inova clinic or Inova hospital setting
  • Left Ventricular Ejection Fraction ≤40%

You may not qualify if:

  • Opted out of EHR-based research
  • Hospice care
  • Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy
  • Prior heart transplant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Inova Health System

Falls Church, Virginia, 22042, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Mitchell Psotka, MD, PhD

    Inova Health Care Services

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Matthew G Dimond, BS

CONTACT

Bhruga Shah, MS, BSN-RN

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 21, 2022

First Posted

June 27, 2022

Study Start

August 25, 2022

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

August 24, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Only aggregate participant data will be reported upon the completion of the project.

Locations